68Ga PSMA in Preprostatectomy Patients

Inclusion Criteria: * Biopsy-proven prostate adenocarcinoma * Intermediate to high-risk disease, defined as one of the following factors: PSA \> 10, T2b or greater, or a Gleason score of 7 or greater * A PSA level resulted within the past 2 months * Planned prostatectomy with lymph node dissection * Karnofsky performance status (KPS) greater than or equal to 50 (ECOG/WHO 0, 1, or 2) within the last 3 months * Must be treatment naïve (not have received neoadjuvant chemotherapy, radiation therapy, hormonal therapy, androgen deprivation therapy, or focal ablation techniques (e.g., HiFu) * Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an IND for initial efficacy investigations * Ability to understand and the willingness to provide informed consent. Exclusion Criteria: * Cannot receive furosemide * Allergy to sulfa or sulfa-containing medications * History of Stevens-Johnson syndrome * Known Paget's disease * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements